论文信息 - Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors - 字舞流文

Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

K. Venkatakrishnan | C. Higano | N. Hahn | Matthew H Taylor | Xiaofei Zhou | J. Sarantopoulos | Bin Zhang | J. Graff | E. Leonard | M. Taylor